Valuation: Gilead Sciences, Inc.

Market Cap 167B 147B 137B 126B 235B 15,974B 241B 1,622B 634B 7,904B 626B 613B 27,325B P/E 2026 *
-48.4x
P/E 2027 * 17x
Enterprise Value 176B 155B 145B 133B 249B 16,893B 255B 1,715B 671B 8,359B 662B 648B 28,898B EV / Sales 2026 *
5.8x
EV / Sales 2027 * 5.16x
Free-Float
99.88%
Yield 2026 *
2.45%
Yield 2027 * 2.54%
1 day-0.31%
1 week+2.71%
Current month+5.96%
1 month+5.97%
3 months+3.90%
6 months-4.07%
Current year+9.07%
1 week 127.61
Extreme 127.61
136.26
1 month 124.19
Extreme 124.19
140.61
Current year 116.88
Extreme 116.88
157.29
1 year 108.46
Extreme 108.4601
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Sell

Executive/Senior Manager

-3,000 0.0002%
7/15/26 Sell

Chief Financial Officer

-3,000 0.0002%
7/1/26 Sell

Chief Executive Officer

-15,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-0.35%+2.71%+17.19%+75.82% 167B
-0.39%+4.74%+59.66%+167.99% 1,089B
+0.21%+4.66%+59.14%+59.69% 643B
+0.98%+5.17%+39.31%+78.10% 465B
-1.69%+8.81%+39.38%+33.67% 359B
-0.51%+3.51%+36.97%+42.46% 303B
+1.50%+3.40%+17.71%+17.41% 267B
+0.79%+5.81%-2.55%-38.10% 226B
-0.89%+6.69%+28.65%+66.79% 212B
+0.06%+1.85%+4.03%-29.89% 144B
Average +0.00%+4.54%+29.95%+47.39% 387.5B
Weighted average by Cap. -0.03%+4.94%+41.36%+77.69%

Financials

2026 *2027 *
Net sales 30.42B 26.73B 24.95B 22.9B 42.87B 2,914B 43.93B 296B 116B 1,442B 114B 112B 4,985B 32.3B 28.38B 26.49B 24.31B 45.51B 3,094B 46.63B 314B 123B 1,531B 121B 119B 5,292B
Net income -3.39B -2.98B -2.78B -2.55B -4.78B -325B -4.9B -32.98B -12.9B -161B -12.73B -12.45B -556B 9.78B 8.59B 8.02B 7.36B 13.78B 937B 14.12B 95.11B 37.2B 464B 36.72B 35.92B 1,602B
Net Debt 9.6B 8.43B 7.87B 7.22B 13.52B 919B 13.86B 93.35B 36.5B 455B 36.03B 35.25B 1,573B -
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-07-29 $133.77 -0.41% 2,412,288
26-07-28 $134.32 +2.91% 6,947,167
26-07-27 $130.52 +0.94% 4,953,801
26-07-24 $129.31 -1.18% 5,529,741
26-07-23 $130.86 +0.40% 6,299,287
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
134.32USD
Average target price
157.15USD
Spread / Average Target
+17.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock